Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?

Key Points

• Fresenius SE & Co. shares rose above their 200-day moving average, reaching $13.0945 before last trading at $12.99, up 0.9% with 97,381 shares traded.
• Analysts remain positive: Morgan Stanley maintained an “overweight” rating, Deutsche Bank reiterated “buy,” and all three tracked analysts rate the stock a Buy.
• The company slightly missed quarterly EPS expectations, reporting $0.24 versus $0.25 forecast, but revenue exceeded estimates at $6.91 billion versus $6.65 billion; analysts expect full-year EPS of $1.08.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $12.91 and traded as high as $13.0945. Fresenius SE & Co. shares last traded at $12.99, with a volume of 97,381 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on FSNUY shares. Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating. According to MarketBeat, the company currently has an average rating of "Buy".

Fresenius SE & Co. Trading Up 0.9%

The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market capitalization of $29.27 billion, a P/E ratio of 16.44 and a beta of 0.60. The firm has a 50 day simple moving average of $12.95 and a two-hundred day simple moving average of $12.91.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. Equities research analysts forecast that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company's activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company's core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.